This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as鈥�
- Investigators
- Brian Stover, William Slayton
- Ages
- 2 Years - N/A
- Sexes
- All